Calcimimetics in the treatment of secondary hyperparathyroisis in dialysis patients: comparison of the efficacy and safety of cinacalcet and etelcalcetide


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Secondary hyperparathyroidism (SHPT), commonly encountered in patients receiving maintenance dialysis, is associated with numerous adverse outcomes, including vascular and valvular calcifications, changes in bone metabolism and an increased risk of cardiovascular morbidity and mortality. Calcimimetics, agents that act on the calcium sensing receptor (CaSR), were designed to overcome limitations in the use of vitamin d sterols to treat shpt, and have demonstrated efficacy in reducing levels of PTH in randomized trials. Currently available calcimimetics include oral cinacalcet (CC) and the recently approved intravenously administered agent, etelcalcetide (EC). while CC is an allosteric modulator of the casr, EC acts as a direct CaSR agonist. Etelcalcetide’s properties allow it to be administered intravenously thrice weekly at the end of a hemodialysis treatment session, which undoubtedly increases adherence to therapy and reduces the burden of using tablet preparations. In randomized clinical trials, EC has been shown to be more effective than CC in reducing levels of PTH, phosphate, calcium, fibroblast growth factor 23 (FGF23). This review compares and contrasts the pharmacologic characteristics of CC and EC, discusses the results of clinical trials involving these drugs, and posits implications for their use for clinical practice.

Full Text

Restricted Access

About the authors

Galina Vladimirovna Volgina

Moscow State University of Medicine and Dentistry named after A.i. Evdokimov of the Ministry of Healthcare of the Russian Federation

Email: volginagv@mail.ru
Prof

References

  1. Moe S., Dru'eke T., Cunningham J. et al. Improving Global Outcomes (KDIGO): Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69:1945-53.
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group: KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2017; 7(1): 1-59. http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKDMBD-GL-Update.pdf.
  3. Arbor Research Collaborative for Health. Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor. Accessed on January 23, 2020. https://www.dopps.org/dpm
  4. Romagnani P., Remuzzi G., Glassock R. et al. Chronic kidney disease. Nat Rev Dis Primers. 2017;3:17088. https://doi.org/10.1038/nrdp.2017.88 PMID: 29168475
  5. Wanner C., Amann K., Shoji T. The heart and vascular system in dialysis. Lancet. 2016; 388(10041) :276-84. https://doi.org/10.1016/S0140-6736(16)30508-6 PMID: 27226133
  6. Hedgeman E., Lipworth L., Lowe K. et al. International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J. Nephrol. 2015;2015:184321.
  7. Vervloet M.G. Chronic Kidney Disease-Mineral and Bone Disorder. Changing Insights Form Changing Parameters? Nephrol Dial Transplant. 2020; 35(3):385-389. https://doi.org/10.1093/ndt/gfz113Cunningham
  8. Portillo M.R., Rodriguez-Ortiz M.E. Secondary Hyperparthyroidism: Pathogenesis, Diagnosis, Preventive and Therapeutic Strategies. Rev Endocr Metab Disord. 2017;18(1):79-95.
  9. Isakova T., Wahl P., Vargas G.S. et al.: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011; 79(12):1370-78.
  10. Munoz-Castaneda J.R., Herencia C., Pendon-Ruiz de Mier M.V. et al. Differential regulation of renal Klotho and FGFR1 in normal and uremic rats. FASEB J. 2017;31(9):3858-67.
  11. Canalejo R., Canalejo A., Martinez-Moreno J.M. et al. FGF23 Fails to Inhibit Uremic Parathyroid Glands. J. Am Soc Nephrol. 2010;21(7):1125-35.
  12. Kawakami K., Takeshita A., Furushima K. et al. Persistent fibroblast growth factor 23 signalling in the parathyroidglandsfor secondary hyperparathyroidism in mice with chronic kidney disease. Sci Rep. 2017;7:40534.
  13. Kan S., Zhang W., Mao J. et al. NF-kB activation contributes to parathyroid cell proliferation in chronic kidney disease. J. Nephrol. 2018;31(6):941-51.
  14. Centeno P.P., Herberger A., Mun H.C. et al. Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun. 2019;10(1):4693. doi: 10.1038/s41467-019-12399-9
  15. Urakawa I., Yamazaki Y., Shimada T. et al. Klotho converts canonical ФРФ receptor into a specific receptor for ФРФ23. Nature. 2006;444(7120):770-74.
  16. Fan Y., Liu W., Bi R. et al. Interrelated role of Klotho and calcium-sensing receptor in parathyroid hormone synthesis and parathyroid hyperplasia. Proc Natl Acad Sci U. S. A. 2018; 115(16):E3749-58.
  17. Sadowski S.M., Pusztaszeri M., Brulhart-Meynet M.C. et al. Identification of Differential Transcriptional Patterns in Primary and Secondary Hyperparathyroidism. J. Clin Endocrinol Metab. 2018;103(6):2189-98.
  18. Shilo V., Mor-Yosef Levi I., Abel R. et al. Let-7 and Micr/RNA-148 Regulate Parathyroid Hormone Levels in Secondary Hyperparathyroidism. J. Am Soc Nephrol. 2017;28(8):2353-63.
  19. Tanaka M., Komaba H., Fukagawa M. Emerging association between parathyroid hormone and anemia in hemodialysis patients. Ther Apher Dial. 2018,22:242-45. doi: 10.1111/1744-9987.12685.
  20. Naylor K.L., Garg A.X., Zou G. et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J. Am Soc Nephrol. 2015, 10:646-53. doi: 10.2215/CJN.06040614.
  21. Tentori F., McCullough K., Kilpatrick R.D. et al. High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney Int. 2014, 85:166-73. 10.1038/ki.2013.279
  22. Chandran M., Wong J. Secondary and tertiary hyperparathyroidism in chronic kidney disease: an endocrine and renal perspective. Indian J. Endocrinol Metab. 2019;23:391-99. doi: 10.4103/ijem.IJEM_292_19.
  23. Kestenbaum B., Katz R., de Boer I. et al. Vitamin D., parathyroid hormone, and cardiovascular events among older adults. J. Am Coll Cardiol. 2011;58:1433- 41. doi: 10.1016/j.jacc.2011.03.069.
  24. Covic A., Kothawala P., Bernal M. et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009; 24:1506-23.
  25. Eknoyan G., Levin A., Levin N.W. Bone metabolism and disease in chronic kidney disease. Am J. Kidney Dis. 2003;42:1-201.
  26. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice Guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 76 (Suppl 113): S1-130.
  27. Tentori F., Fuller D.S., Port F.K. et al. The DOPPS practice monitor for US dialysis care: potential impact of recent guidelines and regulatory changes on management of mineral and bone disorder among US hemodialysis patients. Am J. Kidney Dis. 2014;63(5):851-54.
  28. Aronoff G.R. Consider a step therapy approach for the treatment of hyperparathyroidism and mineral and bone disorder in patients on dialysis. Nephrol News Issues. 2019;33(07):20-3.
  29. Tentori F., Wang M., Bieber B.A. et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J. Am Soc Nephrol. 2015;10:98-10.
  30. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771- 80.
  31. Young E.W., Albert J.M., Satayathum S. et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-87.
  32. Floege J., Kim J., Ireland E. et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl. 2011;26(6):1948-55. doi: 10.1093/ndt/gfq219.
  33. Naves-Diaz M., Passlick-Deetjen J., Guinsburg A. et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transpl. 2011; 26(6):1938-47. doi: 10.1093/ndt/gfq301
  34. Fernandez-Martin J.L., Martinez-Camblor P., Dionisi М.Р. et al. Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transpl. 2015;30(9):1542-51. doi: 10.1093/ndt/gfv099.
  35. Zhou X., Guo Y., Luo Y. The optimal range of serum intact parathyroid hormone for a lower risk of mortality in the incident hemodialysis patients. Ren Fail. 2021;43(1):599-605. doi: 10.1080/0886022X.2021.1903927.
  36. Ketteler M., Block G.A., Evenepoel P. et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26-36.
  37. Asada S., Yokoyama K., Miyakoshi C. et al. Relationship between serum calcium or phosphate levels and mortality stratified by parathyroid hormone level: an analysisfrom the MBD-5Dstudy. Clin Exp Nephrol. 2020;24(7):630-37.
  38. Kato C., Fujii N., Miyakoshi C. et al. Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2020; 21(1):432. doi: 10.1186/s12882-020-02088-x.
  39. Tabibzadeh N., Karaboyas A., Robinson B.M. et al. The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrol Dial Transplant. 2021;36(1):160- 69.
  40. Brown E.M., Gamba G., Riccardi D. et al.: Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366(6455):575-80.
  41. Cunningham J., Locatelli F., Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J. Am Soc Nephrol. 2011;6(4):913-21. https://doi.org/10.2215/ CJN.06040710 PMID: 21454719
  42. Lopez I., Aguilera-Tejero E., Mendoza F.J. et al. Calcimimetic R-568 Decreases Extraosseous Calcifications in Uremic Rats Treated with Calcitriol. J. Am Soc Nephrol. 2006;17(3):795-804.
  43. Lopez I., Mendoza F.J., Guerrero F. et al. The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats. Am J. Physiol Renal Physiol. 2009; 96(6):F1376-85.
  44. Goodman W.G., Quarles L.D. Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int. 2008;74(3):276-88. https://doi.org/10.1038/sj.ki.5002287 PMID: 17568787
  45. Levin A., Bakris G.L., Molitch M. et al. Prevalence of abnormal serum vitamin D., PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71(1):31-38. 17091124' target='_blank'>https://d/i./r7Q10.1038/sj.ki.S002009PMID: 17091124
  46. Block G.A., Martin K.J., de Francisco A.L.M. et al. Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. N. Engl J. Med.2004;350(15):1516-25.
  47. Lindberg J.S., Culleton B., Wong G. et al.: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am Soc Nephrol. 2005; 16(3): 800- 7.
  48. Zitt E., Fouque D., Jacobson S.H. et al. Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction. Clin Kidney J. 2013;6(3):287-94.
  49. Li D., Shao L., Zhou H. et al. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine. 2013;43(1): 68- 77.
  50. Zhang Q., Li M., You L. et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One. 2012; 7(10):e48070.
  51. Raggi P., Chertow G.M., Torres P.U. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D. on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26(4):1327-39.
  52. Urena-Torres P.A., Floege J., Hawley C.M. et al. Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant. 2013;28(1):146-152.
  53. Bellasi A., Reiner M., Petavy F. et al. Presence of valvular calcifcation predicts the response to cinacalcet: data from the ADVANCE study. J. Heart Valve Dis. 2013; 22:391-99.
  54. EVOLVE Trial Investigators Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl J. Med. 2012;367(26):2482-94.
  55. Parfrey P.S., Drueke T.B., Block G.A. et al. The Efects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Clin J. Am Soc Nephrol 2015; 10:791-99.
  56. Pasch A., Block G.A., Bachtler M. et al. Blood calcifcation propensity, cardiovascular events, and survival in patients receiving hemodialysis in the EVOLVE trial. Clin J. Am Soc Nephrol. 2017;12:315-22.
  57. Floege J., Kubo Y., Floege A. et al. The Efect of cinacalcet on calcifc uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE Trial. Clin J. Am Soc Nephrol 2015; 10:800-807.
  58. Wheeler D.C., London G.M., Parfrey P.S. et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) trial. J. Am Heart Assoc. 2014; 3:e001363.
  59. Moe S.M., Chertow G.M., Parfrey PS. et al.: Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation. 2015;132(1):27-39.
  60. Tsuruta Y., Okano K., Kikuchi K. et al. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2013; 17(1):120-26.
  61. Parfrey P.S., Chertow G.M., Block G.A. et al. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J. Clin Endocrinol Metab. 2013;98(12): 4834-44.
  62. Diaz-Tocados J.M., Rodriguez-Ortiz M.E., Almaden Y. et al. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration. Kidney Int. 2019; 95(5):1064-78.
  63. Zitt E., Rix M., Torres P.U. et al. Effectiveness of cinacalcet in patients with recurrent/persistent secondary hyperparathyroidism fo2llowing parathyroidectomy: results of the ECHO study. Nephrol Dial Transplant. 2011;26(6):1956-61.
  64. Edson K.Z., Wu B.M., Iyer A. et al. Determination of etelcalcetide biotransformation and hemodialysis kinetics to guide the timing of its dosing. Kidney Int. 2016;1(1):24-33.
  65. Wu L., Melhem M., Subramanian R., Wu B. Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis. J. Pharmacokinet Pharmacodyn. 2017;44(1):43-53
  66. Martin K.J., Bell G., Pickthorn K. et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and ФРФ23 levels in healthy male subjects. Nephrol Dial Transplant. 2014;29(2):385-92.
  67. Martin K.J., Pickthorn K., Huang S. et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. 2014;85(1):191-97.
  68. Subramanian R., Zhu X., Hock B. et al. Pharmacokinetics, biotransformation, and excretion of [14C] etelcalcetide (AMG 416) following a single microtracer intravenous dose in patients with chronic kidney disease on hemodialysis. Clin Pharmacokinet. 2017;56(2):179-92. PMID: 27517676
  69. Subramanian R., Zhu X., Kerr S.J. et al. Nonclinical pharmacokinetics disposition, and drug-drug interaction potential of a novel D-amino acid peptide agonist of the calcium sensing receptor AMG 416 (etelcalcetide). Drug Metab Dispos. 2016;44(8):1319-31. PMID: 26895981
  70. Block G.A., Bushinsky D.A., Cheng S. et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: A randomized clinical trial. JAMA. 2017;317(2): 156-64. https://doi.org/10.1001/jama.2016.19468 PMID: 28097356
  71. Block G.A., Bushinsky D.A., Cunningham J. et al. Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials. JAMA. 2017;317(2): 146-55. https://doi.org/10.1001/jama.2016.19456 PMID: 28097355
  72. Fukagawa M., Yokoyama K., Shigematsu T. et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant. 2017;32(10):1723-30.
  73. Block G.A., Chertow G.M. Dosing of etelcalcetide vs cinacalcet for secondary hyperparathyroidism-reply. JAMA. 2017;317:2132-33.
  74. Palmer S.C., Mavridis D., Johnson D.W. et al. Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: a systematic review and network meta-analysis. Am J. Kidney Dis. 2020; 76(3):321-30. doi: 10.1053/j.ajkd.2020.02.439.
  75. Shigematsu T., Fukagawa M., Yokoyama K., et al.: Long-term effects of etelcalcetide as intravenous calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2018;22(2):426-36.
  76. Russo D., Tripepi R., Malberti F. et al. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in “Real Life”. J. Clin Med. 2019;8(7):1066.
  77. Cunningham J., Block G.A., Chertow G.M. et al.: Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients. Kidney Int Rep. 2019; 4(7): 987-94.
  78. Xipell M., Montagud-Marrahi E., Rubio M.V. et al. Improved control of secondary hyperparathyroidism in hemodialysis patients switching from Oral Cinacalcet to intravenous Etelcalcetide, especially in nonadherent patients. Blood Purif. 2019;48(2):106-14.
  79. Arenas M.D., Rodelo-Haad C., de Mier M.V.P., Rodriguez M. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics. Clin Kidney J. 2020; 14: 840-46. doi: 10.1093/ckj/sfaa005.
  80. Stephens J.M., Fox K.M., Desai P. Calcimimetic use in US hemodialysis facilities in first 2 years after the launch of etelcalcetide: A descriptive analysis of real-world clinical practice and outcomes. Hemodialysis International. 2021;1-12. Wiley on line library.com/journal/hdi doi: 10.1111/hdi.12996.
  81. Kurokawa Y., Kaida Y., Hazama T. et al. Effect of switching from cinacalcet to etelcalcetide on secondary hyperparathyroidism in patients undergoing hemodialysis: an ESCORT trial. Ren Replace Ther. 2020;6(1):64.
  82. Rottembourg J., Urena-Torres P., Toledano D.et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. Clin Kidney J. 2019;12:871-79.
  83. Karaboyas A., Muenz D., Fuller D.S. et al. Etelcalcetide Utilization, Dosing Titration, and Chronic Kidney Disease-Mineral and Bone Disease (CKD-MBD) Marker Responses in US Hemodialysis Patients. Am J. Kidney Dis. XX (XX):1-12. Published online July 14, 2021. doi: 10.1053/j.ajkd.2021.05.020.
  84. Bushinsky D.A., Chertow G.M., Cheng S. et al. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrol Dial Transplant. 2019;1-10.
  85. Parsabiv (etelcalcetide) injection, for intravenous use [package insert]. KAI Pharmaceuticals Inc/Amgen; 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208325Orig1s000Lbledt.pdf
  86. Shigematsu T., Fukagawa M., Yokoyama K. et al. Effects of the Intravenous Calcimimetic Etelcalcetide on Bone Turnover and Serum Fibroblast Growth Factor 23: Post Hoc Analysis of an Open-label Study. Clin Ther. 2018;40(12):2099-111.
  87. Bell G., Huang S., Martin K.J., Block G.A. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31(5):943-52
  88. Wolf M., Block G.A., Chertow G.M. et al. Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis. Clinical Kidney Journal 2020, 13 (1):75-84. doi: 10.1093/ckj/ sfz034
  89. Dorr К., Kammer М., Reindl-Schwaighofer R. et al. Randomized Trial of Etelcalcetide for Cardiac Hypertrophy in Hemodialysis. Circ Res. 2021;128(11):1616-25
  90. doi: 10.1161/CIRCRESAHA.120.318556
  91. Yu L., Tomlinson J.E., Alexander S.T. et al. Etelcalcetide, a novel calcimimetic, prevents vascular calcification in a rat model of renal insufficiency with secondary hyperparathyroidism. Calcif Tissue Int. 2017;101(6):641-53.
  92. Behets G.J., Spasovski G., Sterling L.R. et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;87(4):846-56. PMID: 25337774
  93. Moe S.M., Abdalla S., Chertow G.M. et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J. Am Soc Nephrol. 2015;26(6):1466-75. PMID: 25505257
  94. Rottembourg J., Ure-na-Torres P., Toledano D. et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. Clinical Kidney Journal, 2019,1-9. doi: 10.1093/ckj/sfz021.
  95. Fielden M.R., Dean C. Jr, Black K. et al. Nonclinical safety profile of etelcalcetide, a novel peptide calcimimetic for the treatment of secondary hyperparathyroidism. Int J. Toxicol. 2016; 35(3):294-308. PMID: 26941242.
  96. Amgen Inc. Swiss summary of the risk management plan (RMP) for Parsabiv (etelcalcetide), Zug, Switzerland.2017 [cited 2018 February22].www.ema.europa.eu/docs/en_GB/document_library/.../WC500217125.pdf
  97. De Geest S., Sabate E. Adherence to long-term therapies: evidence for action. Eur J. Cardiovasc Nurs. 2003;2(4):323. doi: 10.1016/S1474-5151(03)00091-4.
  98. Fuller D.S., Hallett D., Dluzniewski P.J.et al. Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries. BMC Nephrol. 2019;20:169.
  99. Kilpatrick R.D., Newsome B.B., Zaun D. et al. Evaluating real-world use of cinacalcet and biochemical response to therapy in U.S. hemodialysis patients. Am J. Nephrol. 2013;37:389-98.
  100. Reams B.D., Dluzniewski P.J., Do T.P. et al. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective new-user cohort design. BMC Nephrol. 2015;16:175.
  101. Gincherman Y., Moloney K., McKee C., Coyne D.W. Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients. Hemodial Int. 2010;14(1):68-72.
  102. Lee A., Song X., Khan I. et al. Association of cinacalcet adherence and costs in patients on dialysis. J. Med Econ. 2011;14(6):798-804.
  103. Park H., Rascati K.L., Lawson K.A. et al. Adherence and persistence to prescribed medication therapy among Medicare part D. beneficiaries on dialysis: comparisons of benefit type and benefit phase. J. Manag Care Spec Pharm. 2014;20(8):862-76.
  104. Chiu Y.W., Teitelbaum I., Misra M. et al. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J. Am Soc Nephrol. 2009;4(6): 1089-1096.
  105. Burnier M., Pruijm M., Wuerzner G. et al. Drug adherence in chronic kidney diseases and dialysis. Nephrol Dial Transplant 2015;30:39-44.
  106. Friedl C., Zitt E. Role of etelcalcetide in the management of secondary hyperparathyroidism in hemodialysis patients: a review on current data and place in therapy. Drug Des Devel Ther. 2018;12:1589-98
  107. Roggeri A., Conte F., Rossi C. et al. Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs.Drugs Context. 2020;9:2020-2021-1.
  108. Cunningham J., Danese M., Olson K. et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 2005;68(4):1793-800. https://doi.org/10.1111/j.1523-1755.2005.00596.x PMID: 16164656
  109. van der Plas W.Y., Dulfer R.R., Engelsman A.F. et al. Effect ofparathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transplant. 2017;32(11):1902-1908.
  110. Ghimire S., Castelino R.L., Lioufas N.M. et al. Nonadherence to medication therapy in haemodialysis patients: a systematic review. PLoS One. 2015;10(12):e0144119.
  111. Ge Y., Yang G., Wang N. et al. Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism. Int Urol Nephrol. 2019; 51(1):1443-49.
  112. Ivarsson K.M., Akaberi S., Isaksson E. et al. Cardiovascular and cerebrovascular events after Parathyroidectomy in patients on renal replacement therapy. World J. Surg. 2019;43(8):1981-88.
  113. Chertow G.M., Block G.A., Correa-Rotter R. et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl J. Med. 2012;367(26):2482-94. https://doi.org/10.1056/NEJMoa1205624 PMID: 23121374
  114. Block G.A., Chertow G.M., Sullivan J.T. et al. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism. PLoS ONE. 2019:14(3): e0213774. https://doi.org/10.1371/journal.pone.0213774
  115. Block G.A., Martin K.J., de Francisco A.L. et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl J. Med. 2004; 350(15):1516-25.
  116. Floege J., Tsirtsonis K., Iles J. et al. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int. 2018 Mar 7; Epub.
  117. Middleton J.P., Wolf M. Second chances to improve ESRD outcomes with a second-generation calcimimetic. JAMA. 2017;317:139-41.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download